Lumos Pharma Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lumos Pharma Inc 's ROA in the third quarter of 2024?
Lumos Pharma Inc recorded a cumulative net loss of $-35 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -129.88%.

However, within the Healthcare sector 874 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2024 from 4673 to 4720.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter
Y / Y Total Assets Change	-63.43 %	-62.12 %	-55.94 %	-43.79 %	-39.72 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-35	-36	-37	-34	-33
Return On Assets (TTM)	-129.88 %	-103.75 %	-85.93 %	-65.3 %	-54.67 %
LUMO's Total Ranking	# 4720	# 4673	# 4656	# 5210	# 4537
Total Assets (TTM) in million	17	21	28	41	48
Seq. Total Assets Change	-18.23 %	-23.94 %	-30.91 %	-14.9 %	-15.29 %
Seq. Net Income Change	-	-	-	-	-

LUMO's 5 Years Annual ROA >> Back to LUMO Management Effectiveness >> Compare LUMO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 417
Sector	# 875
Overall	# 4629

Return On Assets Statistics
High	Average	Low
82.23 %	-32.28 %	-129.88 %
(Dec 31 2014)		(Sep 30 2024)

Financial Statements
Lumos Pharma Inc 's Assets	$ 17 million	LUMO's Balance sheet
Lumos Pharma Inc 's Income	$ -7 million	Quarterly LUMO's Income Statement
LUMO's Income by Division		See LUMO's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-43.79 %	-27.93 %	-22.26 %	33.32 %	-26.08 %
Total Assets in million	41	72	100	129	97
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-34	-31	-30	-6	-43
Annual Return On Assets	-83.75 %	-42.97 %	-30.34 %	-4.39 %	-44.42 %

LUMO's 5 Years Annual ROA >> Back to LUMO Management Effectiveness >> Compare LUMO ROA to its Competitors

More Return On Assets Ratios
LUMO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LUMO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LUMO's Competitors
Subscribers only: Roa for Lumos Pharma Inc 's Suppliers
Subscribers only: Return On Assets for LUMO's Customers

You may also want to know
LUMO's Roi	LUMO's Inventory Turnover Ratio	LUMO's Growth Rates	LUMO's Dividend Comparisons
	LUMO's Profitability Ratios	LUMO's Asset Turnover Ratio	LUMO's Dividend Growth
LUMO's Roe	LUMO's Valuation Ratios	LUMO's Financial Strength Ratios	LUMO's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:12:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.